DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Study Overview

This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors.

Study Description

The purpose of this study is to evaluate the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy.

Additional Information

Participants will not be paid for their participation.

IRB Number: 1703616209 (S1609)
Research Study Identifier: TX7674
Principal Investigator: Kathy Miller, MD

Recruitment Status

Open

Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required

* Your Email

* First Name

Last Name

* Your Phone

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Recruitment Status

Open

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Study Overview

Study Description

Additional Information

Recruitment Status

Contact the research team to learn more about this study. Fields marked with asterisk (*) are required

Recruitment Status

Volunteer Registry

Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required